One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Medicare Part D Coverage of Antiobesity Medications — Challenges and Uncertainty Ahead
Khrysta Baig, M.S.P.H., Stacie B. Dusetzina, Ph.D., David D. Kim, Ph.D., and Ashley A. Leech, Ph.D.
doi : 10.1056/NEJMp2300516
Vol. 388 No. 11
Eroding Judicial Deference to the FDA — Consequences for Public Health
C. Joseph Ross Daval, J.D., Liam Bendicksen, B.A., and Aaron S. Kesselheim, M.D., J.D., M.P.H.
doi : 10.1056/NEJMp2215193
Pregnancy and Residency — Overdue for Equity
Suzanne Koven, M.D., Jessica E. Haberer, M.D., and Deborah Gomez Kwolek, M.D.
doi : 10.1056/NEJMp2215288
Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants
Ogo Egbuna, M.D., Brandon Zimmerman, Ph.D., George Manos, Ph.D., Anne Fortier, Ph.D., Madalina C. Chirieac, M.D., M.P.H., Leslie A. Dakin, Ph.D., David J. Friedman, M.D., Kate Bramham, M.D., Kirk Campbell, M.D., Bertrand Knebelmann, M.D., Laura Barisoni, M.D., Ronald J. Falk, M.D., Debbie S. Gipson, M.D., Michael S. Lipkowitz, M.D., Akinlolu Ojo, M.D., Mark E. Bunnage, D.Phil., Martin R. Pollak, M.D., David Altshuler, M.D., Ph.D., and Glenn M. Chertow, M.D. for the VX19-147-101 Study Group*
doi : 10.1056/NEJMoa2202396
Persons with toxic gain-of-function variants in the gene encoding apolipoprotein L1 (APOL1) are at greater risk for the development of rapidly progressive, proteinuric nephropathy. Despite the known genetic cause, therapies targeting proteinuric kidney disease in persons with two APOL1 variants (G1 or G2) are lacking.
Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus
Tim Hundscheid, M.D., Wes Onland, M.D., Ph.D., Elisabeth M.W. Kooi, M.D., Ph.D., Daniel C. Vijlbrief, M.D., Ph.D., Willem B. de Vries, M.D., Ph.D., Koen P. Dijkman, M.D., Anton H. van Kaam, M.D., Ph.D., Eduardo Villamor, M.D., Ph.D., André A. Kroon, M.D., Ph.D., Remco Visser, M.D., Ph.D., Susanne M. Mulder-de Tollenaer, M.D., Barbara De Bisschop, M.D., Peter H. Dijk, M.D., Ph.D., Daniela Avino, M.D., Catheline Hocq, M.D., Alexandra Zecic, M.D., Marisse Meeus, M.D., Tessa de Baat, M.D., Frank Derriks, M.D., Tine B. Henriksen, M.D., Ph.D., Kasper J. Kyng, M.D., Ph.D., Rogier Donders, Ph.D., Debbie H.G.M. Nuytemans, Bart Van Overmeire, M.D., Ph.D., Antonius L. Mulder, M.D., Ph.D., and Willem P. de Boode, M.D., Ph.D. for the BeNeDuctus Trial Investigators*
doi : 10.1056/NEJMoa2207418
Cyclooxygenase inhibitors are commonly used in infants with patent ductus arteriosus (PDA), but the benefit of these drugs is uncertain.
Trial of Hybrid Closed-Loop Control in Young Children with Type 1 Diabetes
R. Paul Wadwa, M.D., Zachariah W. Reed, M.S., Bruce A. Buckingham, M.D., Mark D. DeBoer, M.D., Laya Ekhlaspour, M.D., Gregory P. Forlenza, M.D., Melissa Schoelwer, M.D., John Lum, M.S., Craig Kollman, Ph.D., Roy W. Beck, M.D., Ph.D., and Marc D. Breton, Ph.D. for the PEDAP Trial Study Group*
doi : 10.1056/NEJMoa2210834
Closed-loop control systems of insulin delivery may improve glycemic outcomes in young children with type 1 diabetes. The efficacy and safety of initiating a closed-loop system virtually are unclear.
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
Paula Rodriguez-Otero, M.D., Ph.D., Sikander Ailawadhi, M.D., Bertrand Arnulf, M.D., Ph.D., Krina Patel, M.D., Michele Cavo, M.D., Ajay K. Nooka, M.D., M.P.H., Salomon Manier, M.D., Ph.D., Natalie Callander, M.D., Luciano J. Costa, M.D., Ph.D., Ravi Vij, M.D., Nizar J. Bahlis, M.D., Philippe Moreau, M.D., Scott R. Solomon, M.D., Michel Delforge, M.D., Jesus Berdeja, M.D., Anna Truppel-Hartmann, M.D., Zhihong Yang, Ph.D., Linda Favre-Kontula, Ph.D., Fan Wu, Ph.D., Julia Piasecki, B.A., Mark Cook, M.B., Ch.B., Ph.D., and Sergio Giralt, M.D.
doi : 10.1056/NEJMoa2213614
Survival is poor among patients with triple-class–exposed relapsed and refractory multiple myeloma. Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapy, previously led to deep, durable responses in patients with heavily pretreated relapsed and refractory multiple myeloma.
Messenger RNA Translation Defects in Neurodegenerative Diseases
Erik Storkebaum, Ph.D., Kobi Rosenblum, Ph.D., and Nahum Sonenberg, Ph.D.
doi : 10.1056/NEJMra2215795
Malignant Acanthosis Nigricans
Huei-Jing Wang, M.D., Ph.D., and S. Chu-Sung Hu, M.B., B.S., M.Phil.
doi : 10.1056/NEJMicm2207017
Case 8-2023: A 71-Year-Old Woman with Refractory Hemolytic Anemia
Alfred I. Lee, M.D., Ph.D., Pedram Heidari, M.D., Andrew Z. Fenves, M.D., Aditya Bardia, M.D., M.P.H., and Robert Ta, M.D.
doi : 10.1056/NEJMcpc2211370
Inhibiting APOL1 to Treat Kidney Disease
Winfred W. Williams, M.D., and Julie R. Ingelfinger, M.D.
doi : 10.1056/NEJMe2208455
Time to Stop Early Treatment of Patent Ductus Arteriosus?
Carl H. Backes, M.D., and Jonathan L. Slaughter, M.D., M.P.H.
doi : 10.1056/NEJMe2214764
Technology in the Changing Management of Diabetes in Children
Daniela Bruttomesso, M.D., Ph.D.
doi : 10.1056/NEJMe2301252
Audio Interview: The Future of Covid-19 Research
Eric J. Rubin, M.D., Ph.D., Lindsey R. Baden, M.D., and Stephen Morrissey, Ph.D.
doi : 10.1056/NEJMe2302598
